During a live event, Praneeth Baratam, MBBS, discussed the molecular factors that affect staging of lower-risk myelodysplastic syndromes.

Personalized treatment strategies are increasingly important in managing lung cancer brain metastases, incorporating targeted therapies and immunotherapies. Stereotactic radiosurgery and whole-brain ...

Biomarkers such as ring sideroblasts are indicators for response to treatments like luspatercept (Reblozyl). In patients with ...

Image courtesy of the U.S. Centers for Disease Control. Over the past 50 years, survival rates for a group of blood cancers known as myelodysplastic syndrome (MDS) have not improved, despite the ...

AbbVie Inc (NYSE:ABBV) on Monday announced an update from the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine for newly diagnosed higher-risk myelodysplastic syndrome ...

Luspatercept-aamt (Reblozyl) is among National Comprehensive Cancer Network Guideline recommendations for low-risk MDS.

(HealthDay News) — Myelodysplastic syndrome (MDS) is independently associated with incident cardiovascular disease (CVD), according to a study published online Nov. 10 in the Canadian Journal of ...

FORT MYERS, Fla., Sept. 22, 2025 /PRNewswire/ -- Leveraging its proprietary real-world data, Florida Cancer Specialists & Research Institute, LLC (FCS) has concluded the first study to evaluate the ...